Horst G. Zerbe, Ph.D.

CEO. Prior to founding IntelGenx, Dr. Zerbe served as the President of Smartrix Technologies Inc. in Montreal, and as Vice President of R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ. Dr. Zerbe holds over 40 patents in drug delivery related fields and has published numerous scientific papers in recognized journals.

Andre Godin, CPA, CA.

President and Chief Financial Officer, has more than 25 years experience in the Biotech-Pharma industry. He has a strong background in Capital Markets, Finance and Operations. Mr. Godin held several high level positions as CEO, CFO and Vice-President of pharmaceutical and nutraceutical Companies. Mr. Godin is a member of the Canadian Chartered Professional Accountants and the Canadian Institute of Chartered Accountants. He holds a Bachelor of Business Administration degree from Université du Québec à Montreal.

Nadine Paiement, M.Sc.

Vice President, Research and Development. Ms. Paiement has been with IntelGenx since 2005, where she grew into different positions including her most recent position as Senior Director, Research and Development. She is the co-inventor of IntelGenx’s three platform technologies. As Vice President of Research and Development she is responsible for managing the company’s research and development efforts necessary to meet the corporate goals. She is also responsible for advancing the company’s current and emerging product pipeline through early to late stage development and regulatory filing. Her strong background in the pharmaceutical industry encompasses all areas from the laboratory level through to manufacturing scale-up, and during her more than 14 years’ experience she has developed a highly creative approach to the development of new methods and resolving technical issues. She is the co-inventor of four patents and multiple pending applications, and has published articles in various recognized journals.

Dana Matzen, Ph.D.

Vice President, Business and Corporate Development. Dr. Matzen is the former Director, Business Development at Paladin Labs, an Endo International company, based in Montreal, Canada, since May 2010. During her time at Paladin, Dr. Matzen has held responsibilities for in-licensing business opportunities for Canada, Africa and Latin America. She led over 13 transactions which resulted in 7 new product launches. In addition, Dr. Matzen was in charge for overseeing strategic initiatives for Paladin’s international out-licensing business including alliance management of over 15 existing partners worldwide. More recently, Dr. Matzen joined the Marketing Team and led the successful launch of Iclusig in Canada. Prior to joining Paladin, Dr. Matzen was Life Science Specialist at L.E.K. Consulting in London, UK and Los Angeles, U.S. Prior to L.E.K. Consulting, Dr. Matzen was Postdoctoral Scholar at UCSF focusing on cellular and molecular pharmacology. Dr. Matzen has published several peer-reviewed articles that have been referenced in over 100 publications and was awarded with the Genentech Foundation Postdoctoral Fellowship for outstanding research. Dr. Matzen holds a Ph.D in Microbiology and Genetics from the University of Vienna (Max F. Perutz Laboratories) and her Masters in Nutritional Economics from the University Kiel, Germany.

Rodolphe Obeid, Ph.D.

Vice President, Operations. Dr. Obeid is an expert in drug delivery systems and polymeric assemblies, who has developed strong technical expertise across a range of operations functions, with a particular emphasis on oral film manufacturing processes, lean manufacturing practices and continuous improvement initiatives. He has held a number of progressive management positions at IntelGenx. Most recently, he served as IntelGenx’s Senior Director of Operations, with responsibility for the direction, strategy, planning and execution of IntelGenx’s manufacturing operations. In his new role as Vice President, Operations, Dr. Obeid will oversee all operational activities, including manufacturing, packaging, facilities and maintenance, production planning and supply chain management. In addition, he will manage process development and manufacturing scale-up of all internal and external pharmaceutical film projects.

Prior to joining IntelGenx in 2013, Dr. Obeid was a postdoctoral industrial R&D Fellow at the Faculty of Veterinary Medicine of University of Montreal, working on vaccine encapsulation using biodegradable microspheres. Before that, he was a National Institutes of Health Postdoctoral Scholar at the University of Alabama in collaboration with the Massachusetts Institute of Technology, focusing on the development of novel poly-based polymers for surface modification of biomedical implants as a part of the Boston Retinal Implant Project. Dr. Obeid holds a Ph.D. in polymer chemistry from the University of Montreal, Canada and two Masters in polymer science and chemical engineering from the University of Strasbourg, France. Dr. Obeid is the co-inventor of several issued and pending patents, and has published numerous scientific articles in recognized international journals and conferences.